Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03218683 Phase I AZD5991 Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. Terminated USA 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed NLD | GBR | DEU 0
NCT03884998 Phase I Copanlisib + Nivolumab Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma Active, not recruiting USA 0
NCT03892044 Phase I Duvelisib + Nivolumab Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Completed USA 0
NCT04623541 Phase Ib/II Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 3
NCT04978779 Phase I VIP152 A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome Terminated USA 1
NCT05588440 Phase Ib/II Cyclophosphamide + Fludarabine ONCT-808 A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting USA 0
NCT05665530 Phase I PRT2527 A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies Recruiting USA | ITA | GBR | FRA | DEU | CAN | AUS 3
NCT05672173 Phase II Cyclophosphamide + Fludarabine + Ibrutinib + Lisocabtagene maraleucel Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation Recruiting USA 0
NCT05672251 Phase II Loncastuximab tesirine-lpyl + Mosunetuzumab-axgb Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Recruiting USA 0
NCT05873712 Phase II Cyclophosphamide + Fludarabine + Lisocabtagene maraleucel + Zanubrutinib Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome Recruiting USA 0
NCT06043674 Phase II Tocilizumab Atezolizumab + Glofitamab-gxbm + Obinutuzumab Glofitamab-gxbm + Obinutuzumab + Polatuzumab vedotin-piiq Glofitamab-gxbm + Obinutuzumab A Phase 2 Study of Glofitamab as Monotherapy or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation Recruiting USA 0
NCT06191887 Phase I Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Recruiting USA 0
NCT06227026 Phase I Anti-CD19 CAR-T cells Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) Recruiting USA 0
NCT06247540 Phase II Nivolumab + Rituximab + Venetoclax Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Withdrawn USA 0